NovoThirteen

Saxenda (liraglutide 6 mg/mL solution for injection in pre-filled pen) is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by NovoThirteen for the treatment of obesity. The program is currently in Phase 3 development, with an active trial investigating the effect and safety of liraglutide 3.0 mg on weight management in children aged 6 to less than 12 years over a 56-week, double-blind, randomized, placebo-controlled study design. Liraglutide is administered via subcutaneous injection and is classified within the alimentary tract and metabolism therapeutic category (A10). The drug has already achieved regulatory approval in multiple jurisdictions: the European Union (approved November 2024 and June 2025 under multiple marketing authorization holders including Novo Nordisk A/S and STADA Arzneimittel AG), Japan (approved January 2010), and the United States (approved under NDA022341 and NDA206321, with multiple generic versions authorized). The current Phase 3 trial represents a label expansion effort targeting the pediatric obesity population, a previously underserved indication. Key regulatory milestones include ongoing clinical trial activity in China (NCT06361238) and the completion of the pediatric weight management trial, which will inform potential regulatory submissions for pediatric obesity indications.

Childhood obesity represents a significant and growing public health challenge globally, with limited pharmacological treatment options approved for younger populations. The pediatric obesity market remains largely underserved, with few weight-management medications available for children aged 6–11 years. Liraglutide's established safety and efficacy profile in adult obesity, combined with its mechanism of action as a GLP-1 receptor agonist, positions it as a potential therapeutic option for pediatric patients. The Phase 3 trial data will be critical for establishing efficacy and safety in this younger population and may support regulatory submissions for pediatric indications across multiple markets. From a commercial perspective, successful approval in pediatric obesity could expand the addressable market for Saxenda and establish a new treatment paradigm in an indication with significant unmet medical need. The competitive landscape in pediatric obesity pharmacotherapy is sparse, creating a potential first-mover advantage. Additionally, the drug's established regulatory approvals in major markets (EU, US, Japan) provide a foundation for rapid commercialization of any new pediatric indication. The trial's focus on a 56-week duration provides robust evidence of sustained weight management, which is critical for regulatory acceptance and clinical adoption in pediatric populations.

Drug Class: Glucagon-like peptide-1 (GLP-1) receptor agonist

Modality: Small molecule

Route of Administration: Subcutaneous injection (pre-filled pen)

Therapeutic Classification: Alimentary tract and metabolism (A10)

Formulation: 6 mg/mL solution for injection

Related Therapies: Liraglutide is a synthetic analog of human glucagon-like peptide-1 (GLP-1) and belongs to the incretin mimetic class of antidiabetic and weight-management agents. Other GLP-1 receptor agonists exist in the market, though specific competitors are not detailed in the regulatory data provided.

First Approval: Japan (January 2010); European Union (November 2024 and June 2025 for obesity indication under multiple marketing authorization holders); United States (approved under NDA022341 and NDA206321).

Patent Status: Not yet disclosed in available regulatory documentation.

United States (FDA): Liraglutide approved under NDA022341 and NDA206321. Multiple generic applications authorized (ANDA212552, ANDA214568, ANDA215245, ANDA215421, ANDA215503, ANDA217063, ANDA217234, ANDA217590, ANDA218115) from sponsors including Biocon Pharma, Fresenius Kabi USA, Hikma, Lupin, Nanjing King Friend, Novo, Novo Nordisk Inc, Orbicular, and Teva Pharma.

European Union (EMA): Saxenda approved November 19, 2024 (Novo Nordisk A/S, EMEA/H/C/001026, EMEA/H/C/003780, EMEA/H/C/006615, EMEA/H/C/006620) and June 25, 2025 (STADA Arzneimittel AG). Approval status for pediatric obesity indication: not yet disclosed.

Japan (PMDA): Liraglutide approved January 2010.

China (NMPA): Clinical trial status; NCT06361238 active. Full regulatory approval status: not yet disclosed.

Strategic Implications: The Phase 3 pediatric obesity trial represents a deliberate label expansion strategy for Saxenda into an underserved population segment. Success could establish a new standard of care for pharmacological weight management in children and significantly expand the commercial addressable market. The 56-week trial duration is strategically designed to demonstrate sustained efficacy, a critical requirement for pediatric indications.

Competitive Implications: Limited approved pharmacological options for pediatric obesity (ages 6–11) create a first-mover advantage opportunity. If approved, Saxenda could establish market dominance in this indication before competing GLP-1 agonists pursue similar pediatric indications. The competitive landscape data provided does not specify mechanisms for listed competitors, limiting detailed comparative analysis.

Future Catalysts: Primary catalysts include completion and unblinding of the Phase 3 pediatric trial, regulatory submissions in major markets (FDA, EMA, PMDA), and potential approval decisions. Additional catalysts may include real-world evidence generation, health economic studies, and pediatric guideline incorporation.

Expected Milestones: Anticipated milestones include Phase 3 trial completion (timing not yet disclosed), regulatory submissions (anticipated post-trial), and potential approvals in the US, EU, and other markets. Pediatric obesity indication approval could occur within 12–24 months of trial completion, depending on regulatory pathway and submission strategy.